Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Emulate, in Partnership with FUJIFILM Cellular Dynamics, Launches Brain-Chip R1 to Advance Neurological Drug Development

Emulate, Inc., the leading provider of next-generation Organ-on-a-Chip technology, in partnership with FUJIFILM Cellular Dynamics, Inc., a pioneering global developer and manufacturer of human induced pluripotent stem cells (iPSCs), today...

Jazz Pharmaceuticals presents new clinical and translational data for Modeyso™ (dordaviprone) in H3 K27M-mutant diffuse midline glioma at SNO 2025

Jazz Pharmaceuticals plc announced that the company will present five abstracts at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting taking place November 19-23 in Honolulu, Hawaii. The presentations will feature both clinical and...

New long-term data confirms TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to block joint damage in active psoriatic arthritis

Johnson & Johnson announced new data from the Phase 3b APEX study showing that TREMFYA® continued to reduce both signs and symptoms of active psoriatic arthritis (PsA) and inhibit progression of structural damage at 48 weeks. At Week 24, TREMFYA ®...

Marius Pharmaceuticals has expanded its global footprint with Health Canada’s approval of KYZATREX® (testosterone undecanoate) CIII capsules

Marius Pharmaceuticals, Inc. a patient-centric healthcare company committed to advancing innovative therapies for testosterone deficiency, announced that Health Canada has approved KYZATREX® (testosterone undecanoate) CIII capsules. KYZATREX is a...

The BioTech Breakthrough Award has been granted to Asahi Kasei for the Planova™ FG1 Filter

Asahi Kasei Corporation has earned top honors in the 2025 BioTech Breakthrough Awards, winning the Biomanufacturing Innovation of the Year for its Planova™ FG1 virus removal filter, developed by its Asahi Kasei Bioprocess business unit. Designed...

Odyssey Therapeutics Welcomes Dennis Dean, Ph.D., as EVP, Non-Clinical Development

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology,...

HanchorBio Unveils Compelling New Data at SITC 2025 Highlighting the Best-in-Class Potential of HCB101 in Advanced Cancers

HanchorBio Inc. a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced the presentation of two late-breaking abstracts on its lead asset, HCB101, at the 40th...

VTAMA® (tapinarof) Cream, 1%, Demonstrates Early and Consistent Efficacy in Children Aged 2+ with Atopic Dermatitis, According to New Data

Organon a global independent healthcare company with a focus on women’s health, will present results from a sub-analysis of pooled data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials evaluating VTAMA cream versus vehicle at the 2025...

Gilead’s Livdelzi® Shows Sustained Efficacy in PBC, Reducing ALP, Relieving Itch, and Potentially Slowing Disease Progression

Gilead Sciences, Inc. announced new long-term data reinforcing the safety and efficacy profile of Livdelzi® (seladelpar) for people living with primary biliary cholangitis (PBC). Findings support Livdelzi's consistent efficacy and safety outcomes...

PRM Pharma Launches HemiClor® 12.5 mg, the First FDA-Approved Low-Dose Chlorthalidone Tablet for Hypertension

PRM Pharma, LLC announces the nationwide availability of HemiClor® (chlorthalidone) 12.5 mg tablets, the first and only FDA-approved 12.5 mg formulation of chlorthalidone for the treatment of hypertension in adults. This milestone comes as the...

Leukogene Therapeutics’ M2T-CD33 (LTI-214) has received Orphan Drug Designation from the U.S. FDA for the treatment of Acute Myeloid Leukemia

Leukogene Therapeutics Inc. (LTI), a biopharmaceutical company developing next-generation immunotherapies for hematologic and other malignancies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation...

LIfT BioSciences will present preclinical data on its first-in-class Immunomodulatory Alpha Neutrophils at the 40th Society for Immunotherapy of Cancer

LIfT BioSciences, a rapidly emerging biotech and the global leader in neutrophil immunotherapies, announces that preclinical data demonstrating the potential of its first-in-class Immunomodulatory Alpha Neutrophils (IMANs) to restore innate immune...

Data on BIMZELX® (bimekizumab-bkzx) in Hidradenitis Suppurativa Showed Sustained Improvements in Pain and Draining Tunnel Resolution for Three Years

UCB, a global biopharmaceutical company, announced three-year data from the BE HEARD trials for BIMZELX® (bimekizumab-bkzx) in moderate-to-severe hidradenitis suppurativa (HS). BIMZELX, the first and only medicine approved to selectively inhibit...

Phase 2 Data of GC Biopharma's Recombinant Anthrax Vaccine, BARYTHRAX, Demonstrates Safety and Immunogenicity, Published in 'Vaccine

GC Biopharma, a leading global pharmaceutical company based in South Korea, announced that the Phase 2 clinical trial results for its anthrax vaccine 'BARYTHRAX inj. (GC1109)' have been published in the international journal Vaccine. BARYTHRAX is...

Serenity Mental Health Centers: Where to Get TMS Therapy in Colorado Springs

Serenity Mental Health Centers, a leader in innovative psychiatric care and one of the fastest-growing mental health providers in the nation, is setting the standard for TMS therapy in Colorado Springs. Serenity’s board-certified psychiatrists and...

Merz Aesthetics® Introduces New BELOTERO® Syringe, Offering Greater Precision, Comfort, and Ease of Use.

Merz Aesthetics, the world’s largest dedicated medical aesthetics business, announced today the launch of a new syringe for its category-leading hyaluronic acid (HA) brand BELOTERO®. The new syringe is ergonomically engineered to elevate the...

Samsung Epis Holdings, Newly Established, to Drive Growth for Samsung Bioepis and Its New Subsidiary

Samsung Epis Holdings Co., Ltd. announced its establishment as a new investment holding company, following the spin-off of Samsung Bioepis Co., Ltd. from Samsung Biologics (KRX: 207940.KS). Samsung Epis Holdings will be listed on Korea Exchange...

Starting January 2026, Samsung Bioepis will commercialize BYOOVIZ® (ranibizumab) in Europe

Samsung Bioepis Co., Ltd. announced that the company has entered into an Asset Purchase Agreement (APA) with Biogen regarding Samsung Bioepis’ two ophthalmology assets: BYOOVIZ® (ranibizumab), a biosimilar referencing Lucentisi (ranibizumab) and...

Fresenius Kabi’s biosimilars Conexxence® and Bomyntra® (denosumab-bnht) receive interchangeable designation from the FDA

Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical technologies, announced that the U.S. Food and Drug Administration (FDA) designated Conexxence®(1) and Bomyntra®(2)...

During FII Week in Riyadh, Rubedo Life Sciences and SVAX announce a strategic partnership

Rubedo Life Sciences, Inc. a leading AI-driven, clinical-stage biotech specializing in selective cellular rejuvenation medicines, announced a strategic partnership with SVAX during the Future Investment Initiative (FII) week in Riyadh. This...